Today's After-Hours Movers:

Trillium Therapeutics Inc. (NASDAQ: TRIL) 28% HIGHER; $25.0 million (the Transaction). The common shares were offered and sold to Pfizer Inc. in a registered direct offering conducted without an underwriter or placement agent. The offering is expected to close on or about September 10, 2020.

Slack (NYSE: WORK) 18% LOWER; reported Q2 EPS of $0.00, $0.03 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $215.9 million versus the consensus estimate of $209.1 million. Slack sees Q3 2021 EPS of ($0.06)-($0.05), versus the consensus of ($0.05). Slack sees Q3 2021 revenue of $222-225 million, versus the consensus of $223.73 million. Slack sees FY2021 EPS of ($0.14)-($0.13), versus the consensus of ($0.16). Slack sees FY2021 revenue of $870-876 million, versus the consensus of $873.3 million.

Athenex, Inc. (Nasdaq: ATNX) 9.8% LOWER; intends to offer and sell, subject to market conditions, 10,000,000 shares of its common stock in an underwritten public offering.

Novavax, Inc. (NASDAQ: NVAX) 8.5% HIGHER; gains on AZN vaccine setback.

Coupa Software (NASDAQ: COUP) 6.8% LOWER; reported Q2 EPS of $0.21, $0.13 better than the analyst estimate of $0.08. Revenue for the quarter came in at $125.9 million versus the consensus estimate of $118.84 million. Coupa Software sees Q3 2021 EPS of $0.02-$0.03, versus the consensus of $0.05. Coupa Software sees Q3 2021 revenue of $123-124 million, versus the consensus of $122.25 million. Coupa Software sees FY2021 EPS of $0.43-$0.45, versus the consensus of $0.38. Coupa Software sees FY2021 revenue of $496.5-498.5 million, versus the consensus of $491.2 million.

lululemon athletica (NASDAQ: LULU) 6.4% LOWER; reported Q2 EPS of $0.74, $0.19 better than the analyst estimate of $0.55. Revenue for the quarter came in at $902.9 million versus the consensus estimate of $842.49 million.

AstraZeneca (NYSE: AZN) 6.3% LOWER; COVID19 vaccine study put on hold due to suspected adverse reaction in participant in the UK - STAT

Phreesia Inc. (NYSE: PHR) 6.2% LOWER; reported Q2 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $35 million versus the consensus estimate of $31.62 million.

Qorvo (Nasdaq: QRVO) 6% HIGHER; raises Q2 guidance

Vroom, Inc. (Nasdaq: VRM) 5.4% LOWER; announced that it has commenced an underwritten public offering of its common stock. Vroom is offering 9,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the SEC). Vroom expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its common stock at the public offering price, less the underwriting discount.

Babcock & Wilcox (NYSE: BW) 5% HIGHER; sees insider buying from CEO and others

Moderna, Inc. (NASDAQ: MRNA) 4% HIGHER; gains on AZN vaccine setback.

Summit Materials (NYSE: SUM) 3.3% HIGHER; CEO, Anne Noona, bought 66,000 shares on 09/04 at $15.24.

ARAMARK Holdings (NYSE: ARMK) 2.4% HIGHER; Goldman Sachs upgraded from Neutral to Buy with a price target of $36.00 (from $23.00).

HealthEquity (NASDAQ: HQY) 1.8% LOWER; reported Q2 EPS of $0.42, $0.15 better than the analyst estimate of $0.27. Revenue for the quarter came in at $176 million versus the consensus estimate of $171.28 million. HealthEquity sees FY2021 EPS of $1.48-$1.58, versus the consensus of $1.44. HealthEquity sees FY2021 revenue of $720-730 million, versus the consensus of $733.4 million.